about
Adjuvant mitotane treatment for adrenocortical carcinomaRelationship between blood pressure and glucose tolerance in acromegaly.Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma.Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas.Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumorsEvaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas.Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosisLaboratory differentiation of Cushing's syndrome.Secondary hypoadrenalism.Adjunctive treatment of adrenocortical carcinoma.Management of adrenal incidentaloma.Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior.AME position statement on adrenal incidentaloma.Metronomic therapy concepts in the management of adrenocortical carcinoma.Management of adjuvant mitotane therapy following resection of adrenal cancer.Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.Management of adrenal cancer: a 2013 update.Practical treatment using mitotane for adrenocortical carcinoma.Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model.Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link?18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane.Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism.Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy.CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly.The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome.May an altered hypothalamo-pituitary-adrenal axis contribute to cortical bone damage in primary hyperparathyroidism?
P50
Q28305285-94D06928-E618-48FE-8258-1F298DA15EA1Q32026973-D6EFD8AD-3DB0-460D-823B-BC69F9F69E70Q33389231-EDE09B88-13C1-4E69-9B4F-6535B4BF39CDQ33891345-0CF287B9-5F23-45B4-AB3E-DA45C29D7E57Q34075752-E306DDCC-6F1C-407E-A83C-B8BE7EE1D6A3Q34559805-F473684E-F1E5-45DF-A068-402F7B3CC230Q34947066-81BCD389-E6A6-4E7B-9833-90AD28E752D8Q35597963-B3FFF67D-18BE-4997-A48F-93B7AE982947Q35657098-B7B538EB-3070-45A0-ACD5-4D4113FD4476Q35688759-515CEC6C-8DE8-418A-AA27-4D44E051FC6AQ37021846-494A4F39-9D09-4237-BB2F-5B9225350876Q37140817-03A8C8B3-2B58-4018-A048-7F4BA57FFFBAQ37148154-475D14DE-CFF8-49F2-B06B-9B686621DAFBQ37509493-C7E4A660-32D2-4784-83FA-DCACC2482B9AQ37688377-DE99A4EF-8CBF-4BA2-B54D-74B62CF13096Q37763822-D5A787B1-4C9A-4031-92F5-31D7D1ABB18AQ37862478-E847B6F7-4C64-4918-B858-7CAA9DFE4FFEQ37942484-26751D53-6594-48F1-9BE0-AC4C8047F30AQ38019388-D0020B65-A8E3-4D5B-9322-26A4C6D880AFQ38098658-EA8260C2-A5E5-4297-A138-61EC9711924BQ38181425-DC6B650C-F77C-44C9-9AAB-EC0FA06D6E58Q38204606-A75A2CDD-9B1B-4658-8F6C-C711050EA7BEQ38545507-5642564E-3B8E-416D-B5A1-4273966BCE2BQ38929781-8F780A4E-77C4-4FF0-A3D9-92221C8DC8B5Q39132665-BD888BB4-51EC-499D-9A8A-4B0DB8EC9368Q39355860-F134D67C-8F6C-4D8F-B271-5E0CC1555628Q39424270-1E11DD6A-DFB2-4B6C-A108-B4055F9F5D7CQ39714806-7C451184-904D-493D-A6BE-8A852B991BFDQ40180747-3463B32D-A374-4C0E-9DDE-FCE50DD31153Q40415660-4E853BAA-6635-494B-BD56-2EC128D452F9Q40566188-9284D9DD-AE41-4A36-8263-490187C07A01Q41185543-32F067AC-6482-429E-A337-89CA4B9BFA11Q41336499-B9F41680-3DD2-4528-9676-679D0E6036BCQ42269618-053C8D02-BC56-4400-ABF9-D27012D242D5Q43010382-60A10957-28F7-4185-98BA-9FBA22CB8FDFQ43245617-19A39216-4365-44C3-B0E1-7E0541BA3B68Q43430995-6888A84C-ACD3-47DE-8908-92381380680AQ43608913-5B81F9A6-B929-4F3E-8B33-5DBD18FD4B3FQ43622785-EF0729C4-D71C-485D-ACDE-7D38C6EF1152Q43814862-AAEA0888-8E77-4A05-8923-146D4285B4AC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Terzolo
@ast
Massimo Terzolo
@en
Massimo Terzolo
@es
Massimo Terzolo
@nl
Massimo Terzolo
@sl
type
label
Massimo Terzolo
@ast
Massimo Terzolo
@en
Massimo Terzolo
@es
Massimo Terzolo
@nl
Massimo Terzolo
@sl
prefLabel
Massimo Terzolo
@ast
Massimo Terzolo
@en
Massimo Terzolo
@es
Massimo Terzolo
@nl
Massimo Terzolo
@sl
P1053
D-5051-2015
P106
P1153
7006870178
P21
P31
P3829
P496
0000-0002-4171-2851
P569
2000-01-01T00:00:00Z